Mesoblast Limited Q4 FY2026 earnings call

• Commercial Success: Ryoncil achieved a successful first full-year launch with $115 million in net revenue. Insurance coverage now exceeds 98% of U.S. lives, and over 50 treatment centers are onboarded.
• Pipeline Milestones: Completed treatment of all 350 patients in the pivotal Phase 3 trial for chronic low back pain. Received FDA clearance for an Investigational New Drug (IND) application to commence Phase 3 trials for Duchenne Muscular Dystrophy (DMD).
• Adult GVHD Expansion: Initiated a randomized Phase 3 trial for adults with steroid-refractory acute graft-versus-host disease (GVHD), enrolling across more than 40 sites. Compassionate care data shows 76% survival at day 100 for adults failing ruxolitinib, compared to 20-30% with standard third-line therapies.
• Manufacturing & IP: Leveraging a global IP portfolio of over 1,100 patents protecting capabilities beyond 2044. Building mature commercial infrastructure and specialized sales teams focused on transplant centers and specialists.
• Strategic Focus: Prioritizing label expansion for Ryoncil into adult GVHD and rare inflammatory conditions like DMD. Developing second-generation Rex-Limistro Cell platform for blockbuster opportunities in orthopedics and cardiology.

The company operates as a single-product commercial entity with a pipeline of developmental programs. The primary product segment is Ryoncil (mesenchymal stromal cells for pediatric acute graft-versus-host disease). For fiscal year 2026, this segment generated net revenues of $115 million and contributed to gross profits of $110 million (excluding amortization). As the sole revenue-generating asset, it represents 100% of current revenue contribution. Other potential segments (Rex-Limistro Cell for chronic low back pain and inflammatory heart failure) are in Phase 3 clinical trials and have not yet contributed to revenue.

• Revenue Growth: Management expects double-digit growth in Ryoncil revenues over the next 12 months, though specific guidance figures will be assessed mid-year.
• Cash Flow: Net cash usage for the year was $43.8 million, with significant improvement in the second half ($13.4 million vs. $50 million prior year). Management aims to reduce overall cash burn in Fiscal 2027 compared to Fiscal 2026.
• Profitability Timeline: While avoiding specific quarterly targets for becoming cash-flow positive from operations, management explicitly guides towards profitability for the next fiscal year and beyond.
• Capital Allocation: Current cash balance of $103 million and a $125 million credit facility provide sufficient liquidity to fund Phase 3 programs and manufacturing without immediate need for additional capital raises.

• Clinical Trial Outcomes: Failure of the Phase 3 chronic low back pain or adult GVHD trials could significantly impact future revenue streams and stock valuation.
• Regulatory Delays: Although FDA interactions are described as flexible, delays in BLA filings or approvals for label expansions (adult GVHD, DMD) could postpone blockbuster opportunities.
• Competition: Established competitors like ruxolitinib dominate the adult GVHD market; gene therapies are emerging in Duchenne Muscular Dystrophy.
• Execution Risk: Scaling manufacturing and commercial operations for new indications requires precise execution to maintain margins and meet patient demand.
• Financial Dependency: Heavy reliance on a single approved product (Ryoncil) creates concentration risk if sales growth stalls or reimbursement policies change.

Q: Analyst asked for revenue growth guidance for the next fiscal year and justification for selecting Duchenne Muscular Dystrophy (DMD) over other inflammatory diseases given competitive landscape.

A: Management projected double-digit revenue growth but deferred specific numbers until mid-year assessment. Regarding DMD, they emphasized treating children aged 3-4 before ambulatory loss, leveraging the anti-inflammatory mechanism proven in GVHD. They believe early intervention prevents irreversible damage and complements existing gene therapies rather than competing directly, addressing a complete unmet need where current treatments fail to stop T-cell mediated muscle inflammation.

Q: Analyst inquired about enrollment status in the adult GVHD trial, statistical powering, and whether interim analysis results would suffice for a Biologics License Application (BLA).

A: The trial is active across 40+ sites, partnering with major transplant networks. It is powered to detect a response rate increase from ~50% (ruxolitinib alone) to >75% (combination). An interim analysis at 57% enrollment (~100 patients) is designed to declare success early if thresholds are met. Both the interim and full study outcomes have been vetted with the FDA and are considered sufficient support for a BLA filing.

Q: Analyst questioned the feasibility of expanding Ryoncil to earlier-stage adult GVHD patients and discussed timelines for initiating the DMD pivotal trial.

A: Management noted active discussions with the new FDA leadership regarding label extensions, citing regulatory flexibility in cell therapies. They expect meetings this quarter to discuss these pathways. For DMD, the IND is cleared, and site selection/parent group consultations are ongoing. The study is ready to begin immediately upon finalizing operational logistics, aiming for rapid recruitment.

Q: Analyst asked about the necessity for additional capital expenditure to sustain pediatric business growth and overall capital allocation strategy for the next 12 months.

A: CFO Jim O'Brien stated that spending plans for Phase 3 programs are clearly defined. The focus is on controlling costs and reducing cash burn while executing milestones. With strong working capital and long-term debt structure, the balance sheet supports current operations and growth initiatives without requiring immediate external fundraising, prioritizing judicious capital deployment.